Dermata Therapeutics, Inc. - Common Stock (NQ:DRMA)

0.8600 -0.0500 (-5.49%)

Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Dermata Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

12 Health Care Stocks Moving In Monday's After-Market Session ↗

January 24, 2022

Gainers Aptorum Group (NASDAQ:APM) stock m...

Via Benzinga

Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors

January 13, 2022

SAN DIEGO, CA / ACCESSWIRE / January 13, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a clinical-stage biotechnology company focused on the treatment of medical and...

From Dermata Therapeutics

Via AccessWire

Dermata to Present at the H.C. Wainwright BioConnect Conference

January 05, 2022

SAN DIEGO, CA / ACCESSWIRE / January 5, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and...

From Dermata Therapeutics

Via AccessWire

36 Stocks Moving In Tuesday's Mid-Day Session ↗

December 07, 2021

Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares climbed 123.2% to $6.16. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and accessories....

Via Benzinga

54 Biggest Movers From Yesterday ↗

December 08, 2021

Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 66.7% to close at $4.60 on Tuesday. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 23, 2021

Gainers Pasithea Therapeutics (NASDAQ:KTTA) stock increased by 157.46% to $5.69 during Tuesday's pre-market session. The company's market cap stands at $75.1...

Via Benzinga

50 Biggest Movers From Yesterday ↗

November 30, 2021

Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares surged 121.7% to close at $88.24 on Monday after the company announced positive topline results from the GEM-3 Phase 3 trial...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 22, 2021

Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 95.32% to $9.61 during Monday's regular session. Trading volume for iSpecimen's stock is 70.9 million as of...

Via Benzinga

Dermata's Aesthetic Improvement Candidate Fails To Impress - Read Why ↗

November 19, 2021

Dermata Therapeutics Inc (NASDAQ: DRMA) announced data from its Phase 1b proof of concept study evaluating a single treatment of DMT410 to treat multiple aesthetic...

Via Benzinga

68 Biggest Movers From Wednesday ↗

November 26, 2021

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced its IPO at $10 per share. Longeveron Inc. (...

Via Benzinga

Topics Initial Public Offering

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 19, 2021

Gainers SCYNEXIS (NASDAQ:SCYX) stock rose 15.69% to $7.15 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 1.2 million shares...

Via Benzinga

61 Biggest Movers From Yesterday ↗

November 23, 2021

Gainers Longeveron Inc. (NASDAQ: LGVN) shares surged 181.2% to settle at $28.20 on Monday on continued upward momentum after the company last week announced the FDA granted Rare...

Via Benzinga

Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions

November 19, 2021

- Observed improvements in pore size, luminosity, brightness, and overall aesthetic appearance - Duration of effect lasted approximately 3 months - No potential distant spread of toxin observed SAN...

From Dermata Therapeutics

Via AccessWire

52 Biggest Movers From Friday ↗

November 22, 2021

Gainers Greenland Technologies Holding Corporation (NASDAQ: GTEC) shares surged 90.2% to close at $9.89 on Friday. Greenland Technologies highlighted the launch of second...

Via Benzinga

The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial ↗

November 19, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack...

Via Benzinga

Dermata Announces First Patient Enrolled in its Phase 2 Trial of DMT310 for the Treatment of Moderate-to-Severe Rosacea

November 17, 2021

- Topline results expected in second half of 2022 - Rosacea affects about 16 million patients in the U.S. SAN DIEGO, CA / ACCESSWIRE / November 17, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the...

From Dermata Therapeutics

Via AccessWire

Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 15, 2021

- Announced positive topline results from DMT310 proof of concept (POC) study in mild-to-moderate psoriasis - - Closed upsized $18.0 million initial public offering (IPO) on Nasdaq Capital Market - -...

From Dermata Therapeutics

Via AccessWire

Topics Initial Public Offering

Dermata Announces Presentation Details for Its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting

November 12, 2021

SAN DIEGO, CA / ACCESSWIRE / November 12, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and...

From Dermata Therapeutics

Via AccessWire

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More ↗

November 14, 2021

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at...

Via Benzinga

Dermata Announces Virtual Investor Event to Present DMT410 Phase 1b Proof of Concept Results in Aesthetic Skin Conditions

November 11, 2021

SAN DIEGO, CA / ACCESSWIRE / November 11, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and...

From Dermata Therapeutics

Via AccessWire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 19, 2021

Gainers Entasis Therapeutics Hldg (NASDAQ:ETTX) shares moved upwards by 16.72% to $3.63 during Tuesday's pre-market session. The company's market cap stands at $...

Via Benzinga

18 Stocks Moving in Tuesday's Pre-Market Session ↗

October 19, 2021

Gainers Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 26.1% to $2.03 in pre-market trading after surging 18% on Monday. Kaival Brands Innovations recently announced...

Via Benzinga

Dermata Stock Jumps On Positive Psoriasis Candidate Data ↗

October 19, 2021

Dermata Therapeutics Inc (NASDAQ: DRMA) announced topline results from its Phase 1b trial of DMT310 for mild-to-moderate psoriasis. The percentage of treatment...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 18, 2021

Gainers Dermata Therapeutics (NASDAQ:DRMA

Via Benzinga

Dermata Announces Positive Results from Phase 1b Clinical Trial of DMT310 for the Treatment of Mild-to-Moderate Psoriasis

October 18, 2021

- DMT310 achieved a PGA score of 0 or 1 for the target lesion in 29.6% of patients at Week 8 - - DMT310 demonstrated a total PASI score of 0 or 1 for the target lesion in 25.9% of patients at Week 8 -...

From Dermata Therapeutics

Via AccessWire

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗

September 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 29, 2021

Gainers NuCana (NASDAQ:NCNA) stock increased by 22.36% to $2.9 during Wednesday's regular session. The current volume of 77.9 million shares is 21650.59% of NuCana...

Via Benzinga

Dermata Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update

September 27, 2021

- Completed oversubscribed $18 million Initial Public Offering (IPO) - - Set to announce topline results from its DMT310 Phase 1b proof of concept (POC) study in mild to moderate psoriasis in 4Q 2021 -...

From Dermata Therapeutics

Via AccessWire

Topics Initial Public Offering Intellectual Property

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 22, 2021

Gainers Regencell Bioscience (NASDAQ:

Via Benzinga

50 Biggest Movers From Yesterday ↗

September 23, 2021

Gainers Marin Software Incorporated (NASDAQ: MRIN) shares jumped 61.9% to close at $9.21 on Wednesday following an announcement from management that the company entered into a...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.